Abstract:Background Colorectal cancer (CRC) remains a leading cause of cancer-related deaths worldwide. The current standard of care for patients may involve surgery, chemotherapy, and immune checkpoint inhibitors (ICIs), but these approaches typically fail to secure durable responses against late-stage disease. Regorafenib (REG) is an FDA approved tyrosine kinase inhibitor with immunomodulating properties (inciting, for example, immunogenic cell death [ICD]) for CRC patients who progress on standard care, but 5-year relative survival rates for individuals dosed with the drug as a monotherapy are poor. We hypothesize that REG may be more appropriately leveraged alongside immunotherapeutic agents that specifically stimulate T cell infiltration and activation within the tumor microenvironment (TME). We, therefore, engineered a PD-L1 x CD3 bispecific antibody (bsAb) that simultaneously binds PD-L1-expressing CRC cells and activates nearby T cells in order to investigate combination strategies with REG in pre-clinical models of CRC. Methods REG's ability to induce ICD was evaluated by assessing calreticulin expression by flow cytometry and ATP release through luminescence from MC38 and CT26 CRC cells in vitro. A PD-L1 x CD3 bsAb was next engineered, transiently expressed in Expi293 cells, purified through affinity chromatography, and tested for binding cognate ligands and stimulating T cell function through flow cytometry and ELISA. Lastly, the anti-tumor and immune-driven roles of REG + bsAb therapy were explored in MC38 and CT26 in vivo models using a compilation of IHC, IF, qPCR, and ELISA techniques. Results Our in vitro data overall confirm ICD-induction by REG and demonstrate selective binding and T cell stimulation using a newly designed PD-L1 x CD3 bsAb. Combined REG + bsAb therapy also safely initiated and sustained inhibition against MC38 and CT26 progression in vivo, and these effects correlated to improved CD8+ T cell infiltration and activity within a Type-1-prone TME. Additionally, cytotoxic CD8+ T cells from REG + bsAb-sensitized mice more readily engaged tumor cells than animals treated with either agent alone. Conclusions We provide evidence that the immunomodulatory benefits of REG can be effectively paired with a bsAb that works to anchor to CRC cells, diminish immunosuppression (through PD-L1 blockade), and activate/sustain antigen-specific CD8+ T cells within the TME. This newly described REG + bsAb regimen led to improved anti-tumor outcomes pre-clinically, and may represent a promising future approach for CRC patients. Citation Format: Izuchukwu F Okpalanwaka, Elizabeth A Daugherity, Amanda L McCormick, Trevor S Anderson, Savanna L Smith, Caryn Lawrence, Devin B Lowe. A PD-L1 x CD3 bispecific antibody enhances the anti-tumor efficacy of regorafenib in pre-clinical colon cancer models [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Tumor Immunology and Immunotherapy; 2024 Oct 18-21; Boston, MA. Philadelphia (PA): AACR; Cancer Immunol Res 2024;12(10 Suppl) nr B010.

A novel bivalent anti-c-MET/PD-1 bispecific antibody exhibits potent cytotoxicity against c-MET/PD-L1-positive colorectal cancer

A Novel Bispecific C-Met/Pd-1 Antibody with Therapeutic Potential in Solid Cancer

A novel tetravalent bispecific antibody targeting programmed death 1 and tyrosine-protein kinase Met for treatment of gastric cancer

Generation and Characterization of a Bispecific Antibody Targeting Both PD-1 and C-Met.

Abstract 2617: BCG022, a novel HER3 × MET bispecific antibody-drug conjugate (bsADC), demonstrates promising anti-tumor efficacy

Antibody-drug Conjugate PCMC1D3-Duocarmycin SA as a Novel Therapeutic Entity for Targeted Treatment of Cancers Aberrantly Expressing MET Receptor Tyrosine Kinase

Development of Bispecific Anti-C-met/pd-1 Diabodies for the Treatment of Solid Tumors and the Effect of C-Met Binding Affinity on Efficacy.

A bispecific antibody targeting HER2 and PD-L1 inhibits tumor growth with superior efficacy

Abstract LB212: BCG022: A novel bispecific antibody-drug conjugate targeting HER3 and MET

IgG-like Bispecific Antibody CD3×EpCAM Generated by Split Intein Against Colorectal Cancer

Synergistic Antitumor Effects of Cmet Inhibitor in Combination with Anti-Vegf in Colorectal Cancer Patient-Derived Xenograft Models

Polymeric PD1/PDL1 Bispecific Antibody Enhances Immune Checkpoint Blockade Therapy

In vitro and in vivo antitumor effect of a trivalent bispecific antibody targeting ErbB2 and CD16.

A novel bispecific nanobody with PD-L1/TIGIT dual immune checkpoint blockade

Bispecific antibody targeting both B7-H3 and PD-L1 exhibits superior antitumor activities

A bispecific antibody targeting GPC3 and CD47 induced enhanced antitumor efficacy against dual antigen-expressing HCC

The enhanced antitumor activity of bispecific antibody targeting PD-1/PD-L1 signaling

Abstract 6364: The bispecific antibody KA-3006 against both EGFR and MET surpasses amivantamab in efficacy

Development and Characterization of a Lysosome-Targeting SLC3A2/PD-L1 Bispecific Antibody-Drug Conjugate for Enhanced Anti-Tumor Efficacy in Solid Tumors

Novel bispecific antibody-drug conjugate targeting PD-L1 and B7-H3 enhances antitumor efficacy and promotes immune-mediated antitumor responses

Abstract B010: A PD-L1 x CD3 bispecific antibody enhances the anti-tumor efficacy of regorafenib in pre-clinical colon cancer models